A5021161149- Infectious Diseases and Tuberculosis
- Mycobacterium research and diagnosis
- Tuberculosis Research and Epidemiology
- Streptococcal Infections and Treatments
- Orthopedic Infections and Treatments
- Actinomycetales infections and treatment
- Total Knee Arthroplasty Outcomes
- Diagnosis and treatment of tuberculosis
- Vector-borne infectious diseases
- Osteomyelitis and Bone Disorders Research
- Pneumonia and Respiratory Infections
- Toxoplasma gondii Research Studies
- Legionella and Acanthamoeba research
- Orthopaedic implants and arthroplasty
- Antibiotics Pharmacokinetics and Efficacy
- Pressure Ulcer Prevention and Management
- Amoebic Infections and Treatments
- Pharmaceutical studies and practices
- Antifungal resistance and susceptibility
- Diabetic Foot Ulcer Assessment and Management
- Fungal Infections and Studies
University of Colorado Anschutz Medical Campus
2020-2025
University of Colorado Denver
2019-2023
University of Colorado Hospital
2019-2023
The Medical Center of Aurora
2022
Abstract The optimal treatment of prosthetic joint infection (PJI) remains uncertain. Patients undergoing debridement, antibiotics, and implant retention (DAIR) receive extended antimicrobial treatment, some experts leave patients at perceived highest risk relapse on suppressive antibiotic therapy (SAT). In this narrative review, we synthesize the literature concerning role SAT to prevent failure following DAIR, attempting answer 3 key questions: (1) What factors identify for after DAIR (ie,...
Background Vancomycin-resistant enterococcus (VRE) infections pose substantial challenges for the treatment and suppression of bone joint infections. Oritavancin, a long-acting lipoglycopeptide antibiotic, has shown promising in vitro activity against VRE. Limited data are available on using oritavancin caused by VRE, both (therapy to eliminate active infection) suppressive antimicrobial therapy (long-term antibiotic administration prevent infection recurrence patients at high risk that...
Tedizolid has activity against Gram-positive pathogens as well Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability clinical success of tedizolid is lacking. Prolonged therapy (median, 188 days; interquartile range, 62-493 days) appeared to be tolerated in 37 patients (8.1% experienced adverse effect leading discontinuation). Clinical was 81.3% those evaluated.
Background: Many patients with decubitus-related osteomyelitis are ineligible for myocutaneous flapping, and optimal management in this population is unknown. We describe treatments outcomes of hospitalized decubitus ulcer-related who did not undergo surgical reconstruction or coverage. Methods: systematically identified diagnoses pelvic, sacral, femoral due to ulceration between 1 January 2018 31 December 2018. Demographics, comorbidities, laboratory data, were collected by manual chart...
Atypical mycobacterial infections of the spine can be difficult to treat and represent a subset vertebral osteomyelitis diskitis spectrum often requiring early aggressive surgical intervention. The purpose this review is improve understanding approach disease management from perspective surgeon.
This report describes a histoplasma capsulatum total knee prosthetic joint infection (PJI) in an immunosuppressed patient treated with 2-stage revision. The diagnosis of PJI was made based on minor criteria, and the causative organism identified from cultures obtained at time explantation. underwent induction amphotericin B, followed by oral antifungal therapy successful revision hinged prosthesis interval ∼7 months between stage 1 2. At most recent follow-up (18 months), she remained clear...
We present a case of patient with chronic Q fever who presented digital necrosis, autoamputations, and positive anticentromere antibody, mimicking scleroderma vasculopathy or thromboangiitis obliterans. Coxiella burnetii infection has long been associated the presence autoantibodies autoimmune phenomena including vasculitis. Clinicians should consider testing in patients new-onset diseases appropriate exposure histories.
Abstract Background Tedizolid is an oxazolidinone antibiotic with broad-spectrum Gram-positive activity approved for the treatment of skin and structure infections a 6-day course. Oxazolidinone antibiotics represent appealing options prolonged antimicrobial therapy due to their available oral formulations excellent bioavailability potent in vitro against various multidrug-resistant organisms, Mycobacterium spp., Nocardia spp. Although tedizolid linezolid offer similar clinical spectrum based...